Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model
Beatrice Anna Zannetti(University of Bologna), Francesco Lanza(Ospedale "Santa Maria delle Croci" di Ravenna), Angelo Corso Faini(Fondazione Ricerca Molinette), Massimo Geuna(A. O. Ordine Mauriziano di Torino), Enrico Maffini(Istituto di Ematologia di Bologna), Giovanni Martinelli(University of Bologna), Claudio Cerchione(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Giovanni Poletti(Universidad Peruana Cayetano Heredia), Evita Massari(Azienda Unità Sanitaria Locale Della Romagna), Fabio Malavasi(Fondazione Ricerca Molinette)
Cited by 20
Related Papers
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia
|New England Journal of Medicine|2005|644